Bio-Rad Laboratories Hits New 52-Week High of $364.99

Bio-Rad Laboratories, Inc. has reached a significant milestone by hitting a new 52-week high of USD 364.99 on August 13, 2026. This achievement underscores the company's strong performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 7,235 million. Over the past year, Bio-Rad has demonstrated a robust performance, recording a 26.98% increase, which notably outpaces the S&P 500's growth of 20.6%. The company's price-to-earnings (P/E) ratio stands at 21.00, reflecting its valuation relative to earnings, while its price-to-book ratio is 0.97, indicating a favorable position in terms of asset valuation. Additionally, Bio-Rad maintains a low debt-to-equity ratio of -0.04, suggesting a conservative approach to leverage. The return on equity is reported at 4.65%, highlighting the company's efficiency in generating profits from shareholders' equity. With no dividend yield currently offered, the focus remains on growth and capital appreciation as Bio-Rad continues to navigate the competitive landscape of its industry.